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Abstract
A growing number of arenaviruses are known to cause viral hemorrhagic fever (HF), a severe and life-threatening syndrome
characterized by fever, malaise, and increased vascular permeability. Ribavirin, the only licensed antiviral indicated for the
treatment of certain arenaviral HFs, has had mixed success and significant toxicity. Since severe arenaviral infections initially
do not present with distinguishing symptoms and are difficult to clinically diagnose at early stages, it is of utmost importance
to identify antiviral therapies effective at later stages of infection. We have previously reported that T-705, a substituted
pyrazine derivative currently under development as an anti-influenza drug, is highly active in hamsters infected with Pichinde
virus when the drug is administered orally early during the course of infection. Here we demonstrate that T-705 offers
significant protection against this lethal arenaviral infection in hamsters when treatment is begun after the animals are ill and
the day before the animals begin to succumb to disease. Importantly, this coincides with the time when peak viral loads are
present in most organs and considerable tissue damage is evident. We also show that T-705 is as effective as, and less toxic
than, ribavirin, as infected T-705-treated hamsters on average maintain their weight better and recover more rapidly than
animals treated with ribavirin. Further, there was no added benefit to combination therapy with T-705 and ribavirin. Finally,
pharmacokinetic data indicate that plasma T-705 levels following oral administration are markedly reduced during the latter
stages of disease, and may contribute to the reduced efficacy seen when treatment is withheld until day 7 of infection. Our
findings support further pre-clinical development of T-705 for the treatment of severe arenaviral infections.
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Introduction
The number of highly pathogenic arenaviruses that can cause a
severe syndrome known as viral hemorrhagic fever (HF) has
recently expanded with the addition of Chapare virus to the
growing list that includes Junin, Guanarito, Machupo, Sabia, and
Lassa viruses [1]. Humans are believed to contract arenaviral HFs
through contact with excreta from persistently infected rodents that
serve as reservoirs for these viruses [2]. As a consequence of the
growing human population and its encroachment into previously
unpopulated areas, there is an increased opportunity for co-
habitation between humans and the rodents that harbor highly
pathogenic arenaviruses. The increasing frequency of human
activity in areas where there is potential for inhalation of
aerosolized infected rodent excrement will almost certainly lead
to the discovery of additional arenaviral human pathogens.
Importantly, the fact that these viruses are all infectious via aerosol
exposure increases the potential for their use as bioterror agents [3].
Studies investigating ribavirin usage for the treatment of Lassa
fever (LF), and Argentine and Bolivian HFs, suggest that it may
have some utility [4,5,6]. However, in addition to concerns
regarding toxicity and lack of specificity, the most compelling
evidence for ribavirin application is based on a single human study
employing a historical control group, wherein ribavirin therapy
produced mixed results in treating severe LF cases [6]. When
given within 6 days of disease onset, intravenous ribavirin
dramatically reduced mortality in patients considered to be at
greatest risk, whereas those starting therapy after that window of
treatment initiation did not fare as well. Ribavirin is the only drug
that has been recommended for use in treating arenaviral HFs
under emergency provisions [7]; however, it has not been
approved by the FDA for this indication. The idea of approving
ribavirin, a drug known to induce hemolytic anemia, as a standard
treatment for arenaviral HFs, where blood loss can be associated
with severe disease, must be carefully considered.
There is an important need for safe and effective antivirals with
broad-spectrum activity encompassing multiple RNA virus
families. The demonstrated activity of T-705 (6-fluoro-3-hy-
droxy-2-pyrazinecarboxamide), a novel pyrazine derivative, in
successfully treating in vitro and in vivo viral infections caused by a
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[8], bunyaviruses [8], flaviviruses [9](J. Julander, unpublished
data), picornaviruses [10], orthomyxoviruses [10,11,12], para-
myxoviruses [10], and togaviruses (J. Julander, unpublished data),
is remarkable. Although much work remains to be done, the lack
of toxicity and apparent broad-spectrum activities of T-705 are
very encouraging in that T-705 may provide therapeutic solutions
for multiple viral diseases. T-705 is currently in clinical
development for the treatment of influenza virus infections in
Japan and the USA [13]. Approval for use in treating seasonal and
highly pathogenic avian influenza would facilitate approval for
other indications, as PK, safety testing, and dosing data will be
available from the clinical trials.
We have recently reported that T-705, recognized primarily for
its remarkable activity against a variety of influenza virus
infections in mice [10,11,12], was highly active in cell culture
against several arenaviruses (Tacaribe, Junin, and Pichinde), with
considerably less toxicity and superior selectivity indices com-
pared to ribavirin [8]. More importantly, T-705 was also
efficacious in vivo in the Pichinde virus (PICV) hamster infection
model of arenaviral HF [14]. As biosafety level 4 (BSL-4)
maximum containment facilities required for working with
arenaviral HF agents are not readily available to most
researchers, the less biohazardous PICV infection model (BSL-
2) has facilitated early stage preclinical evaluation of T-705 and
other drugs [8,15,16,17]. As the previous studies were directed at
establishing proof-of-concept, T-705 treatments were initiated
within 72 h after challenge with a lethal dose of PICV [8],
consistent with prophylactic use in the event accidental laboratory
infection where therapeutic intervention could be started early.
Since there is a clear need for antiviral therapies that are effective
during the later stages of severe arenaviral infections, here we
report the use of T-705 for treating advanced PICV disease in
hamsters.
Materials and Methods
Animals and virus
Female 7–8 week-old Syrian hamsters were obtained from
Charles River Laboratories (Wilmington, MA). Animals were
acclimated to the Laboratory Animal Research Facility at Utah
State University for 6–7 days prior to use. Experimental
procedures involving hamsters complied with USDA guidelines
and were approved by the Utah State University Institutional
Animal Care and Use Committee.
PICV, strain An 4763, was provided by Dr. David Gangemi
(Clemson University, Clemson, South Carolina). The viral stock
was prepared following a single passage through hamsters and was
the same as that used in previously published reports [8,15,16].
Briefly, the stock was generated by homogenization of pooled
livers harvested from infected hamsters. Homogenates were
clarified by high-speed centrifugation, aliquoted, and stored at
280uC. The stock virus concentration was ,1610
8 plaque-
forming units per ml. Virus was prepared for inoculation in
minimal essential medium and given bilaterally in two intraper-
itoneal (i.p.) injections of 0.1 mL.
Antiviral drugs
T-705 was kindly provided by the Toyama Chemical Company,
Ltd. (Tokyo, Japan) and suspended in 0.4% carboxymethylcellu-
lose (CMC). Ribavirin was supplied by ICN Pharmaceuticals, Inc.
(Costa Mesa, CA) and was dissolved in sterile saline solution. All
treatments were given by oral gavage (p.o.).
Hamster PICV challenge and antiviral treatment studies
For all experiments, hamsters were weighed prior to the start of
experiments and sorted into groups of 15–25 hamsters so that
mean group weights across the entire experiment varied by less
than 5%. Hamsters were challenged i.p. with ,2 plaque-forming
units of PICV. Groups of hamsters received treatments as specified
in the figure legends or Table 1. Five animals from each treatment
groupweresacrificedonday7ofinfectiontomeasureviralloadsand
serum alanine aminotransferase (ALT) activity. Serum was collected
for assaying systemic viral burden and ALT activity. Livers were
harvestedand homogenized forviraltiterdeterminationasdescribed
below.Theremaining10–20animalsineachgroupwereheld21–28
daysforobservation.Severalsham-infectedanimalswereincludedin
each experiment as normal controls in order to establish reference
values for all tested parameters. In several experiments, mean group
or individual hamster weights were determined periodically through
the duration of the study to assess illness, recovery, and general
health status.
For the study of temporal analysis of PICV tissue viral titers and
other disease parameters hamsters in each group were challenged
with ,2 PFU of PCV. Groups of PICV-challenged hamsters were
sacrificed daily over the course of 10 days. Serum, liver, spleen,
lung, kidney, intestine and brain tissue were collected from each
animal at the time of sacrifice. Serum was collected for assaying
ALT, aspartate aminotransferase (AST) and type I interferon
(IFN) amounts, and virus titers were determined for serum and
clarified tissue homogenates as described below.
Determination of infectious virus in serum and tissues
Virus titers were assayed using an infectious cell culture assay as
previously described [17]. Briefly, a specific volume of tissue
homogenate or serum was serially diluted and added to triplicate
wells of BS-C-1 (African green monkey kidney) cell monolayers in
96-well microplates. The viral cytopathic effect (CPE) was
determined 7–8 days post-virus inoculation and the 50% end-
points were calculated as described [18]. The assay detection
range was 2.75–9.5 log10 cell culture 50% infectious doses
(CCID50)/g of tissue or 1.75–8.5 CCID50/ml of serum. For
statistical analysis of samples presenting with undetectable tissue or
serum virus, a value of 2.75 or 1.75 log10 was assigned,
respectively. In cases where virus exceeded the detection range,
a value of 9.5 or 8.5 log10 was assigned. Thus, where samples are
shown to be at the outer limits of detection, group mean viral loads
may be an over- or under-representation of the actual burden.
Serum ALT and AST determinations
Serum ALT concentrations were measured using a kinetic assay
employing the ALT (SGPT) Reagent Set from Pointe Scientific,
Inc. (Lincoln Park, MI). Serum AST concentration were measured
using the AST Reagent Set from Teco Diagnostics (Anaheim,
CA), which is a colorimetric endpoint assay. Assays were
performed in accordance to the manufacturer’s recommendations,
adjusting the reagent volumes for both assays for analysis of
samples in 96-well microplate format.
Hamster type I IFN bioassay
Induction of type I IFN was determined using a bioassay adapted
for the hamster system from previously described methods [19].
Briefly, baby hamster kidney (BHK-21) cells seeded in 96-well half-
growth area, clear bottom, white opaque polystyrene microplates
were pre-incubated with serially diluted serum samples. After a 6–8
hour pre-incubation period, a predetermined amount of the Indiana
strain of vesicular stomatitis virus (VSV) was added to each well,
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to inhibit cell death (cytopathic effect; CPE) was evaluated. Upon
reaching .80% CPE by visual examination (18–24 h post-
infection), cell viability across the entire plate was measured by
assaying for the presence of ATP using the Cell-Titer GloH system
from Promega (Madison, WI). Luminescence was read on a LB960
Centro luminometer from Berthold Technologies (Oak Ridge, TN).
TypeI IFNtiterswere based on a 50%reduction ofviral cytotoxicity
and were determined by regression analysis.
Analysis of plasma T-705 concentrations following oral
treatment of infected and uninfected hamsters
Groups of 3 hamsters each were either inoculated i.p. with ,5
PFU of PICV or sham-infected. On day 7 of the infection, animals
were given 50 mg/kg T-705 p.o. and animals were sacrificed for
plasma collection at 0.25, 0.5, 1, 2 and 4 h following treatment for
pharmacokinetic (PK) analysis of T-705 and its primary (dead-end)
metabolite, T-705M1 (6-fluoro-3,5-dihydroxy-2-pyrazinecarboxa-
mide). Plasma was deproteinized by the addition of equal volume
of acetonitrile/methanol (1:1) and the clarified solution was
evaporated prior to reconstitution in the mobile phase for high-
pressure liquid chromatography (HPLC) analysis.
Separation and quantitation of T-705 and T-705M1 (devoid of
antiviral activity) were performed by HPLC. Briefly, 100-mls a m p l e s
were analyzed using a Varian HPLC system (Varian Chromatog-
raphy Systems, Woburn, MA) fitted with a Thermo Scientific
4.6 mm625 cm Hypersil ODS C-18 reverse phase column using an
isocratic buffer comprised of 1% acetonitrile in 100 mM triethy-
lammonium phosphate (prepared with phosphoric acid titrated to
pH 6.5 with triethylamine) [20]. An optical density tracing during
the separation was made at 360 nm using an integrator (Shimadzu
Instruments,Columbia,MD).Retentiontimeswereapproximately8
and 11 minutes for the T-705M1 metabolite and T-705, respec-
tively. A standard curve was run using T-705 and T-705M1 at 1, 4,
10, 40, and 100 mg/ml. Using this curve, peak areas of samples were
converted to mg/ml plasma concentrations.
Statistical analysis
Kaplan-Meier survival plots were generated using the Prism
software package (GraphPad Software, San Diego, CA). Survival
curves were compared using the log-rank test. The Mann-Whitney
test (two-tailed) was performed to analyze the differences in mean
virus titers and serum ALT levels.
Results
Virologic and disease parameter values during the course
of PICV infection
It is important to assess animal efficacy data in the context of the
natural history of disease. To do this, landmark events indicative of
disease must be established. The data presented in Figure 1
indicate the times at which viral burden becomes apparent and
when peak levels are reached during PICV infection in adult
hamsters. Systemic viral burden was not apparent until the fifth
day of the infection (Figure 1A). By day 7, near maximal titers of
7.5–8.5 log10 were seen in most hamsters. In contrast, modest
levels of liver virus were detectable as early as day 2, gradually
increasing until reaching peak levels of .8.5 log10 by day 7
(Figure 1B). Modest splenic viral loads were also detectable by day
2 and fluctuated only slightly through day 6 of the infection, with
mean titers ranging from 5.8 to 6.8 log10 (Figure 1C). Peak spleen
viral titers of ,8 log10 were seen from days 7–9. Our studies
confirmed the conclusions of others that liver and spleen are the
major target organs in hamsters infected with PICV [21].
A previous study based on PICV infection of weanling age
hamsters reported high kidney, lung, and brain viral titers [17]. In
this study, we examined these same tissues, as well as the intestines,
for viral burden. Kidney viral titers showed a similar trend to that
Table 1. Effect of a seven-day, twice daily, oral T-705 and ribavirin combination treatment initiated on day 5 of PICV infection in
hamsters.
Disease parameter
b
Mean weight Mean virus titer
c6SD
Treatment Dosage/kg/day Surv/total Day 28 (g) MDD
a6SD Liver Serum ALT
d6SD
T-705+Ribavirin 50 mg+30 mg 5/10 142 24.063.5*** 5.861.1 (100)** ,3.761.5 (100)** 30621**
T-705+Ribavirin 10 mg+30 mg 5/10 113 21.262.2*** 6.860.6 (100)** 5.060.9 (100)** 27629**
T-705+Ribavirin 0 mg+30 mg 6/10* 104 22.063.6*** 6.960.9 (100)** 4.861.2 (100)** 23629**
T-705+Ribavirin 50 mg+6 mg 8/10** 131 14.569.2 6.761.2 (100)** ,3.961.3 (80)** 2396226**
T-705+Ribavirin 10 mg+6 mg 2/10 108 12.865.7* 6.861.3 (100)** ,5.161.8 (100)** 4206486 **
T-705+Ribavirin 0 mg+6 mg 5/10 96 11.665.3 8.160.5 (100)* .7.360.9 (100) 7946441**
T-705+Ribavirin 50 mg+0 mg 3/10 148 14.165.1** .8.460.8 (100) .6.661.6 (100)* 146061308
T-705+Ribavirin 10 mg+0 mg 1/10 142 8.960.9 .8.861.2 (100) .8.260.4 (100) 267861833
T-705+Ribavirin 0 mg+0 mg 4/20 120 8.861.6 .9.260.4 (100) .8.260.4 (100) 25176605
T-705 100 mg 10/10*** 134 .28 5.660.8 (100)** ,3.661.8 (80)** 2566252**
Ribavirin 60 mg 10/10*** 113 .28 6.360.9 (100)** ,4.561.7 (100)** 1667**
Sham-infected - 4/4 168 .28 ,2.8 (0) ,1.8 (0) 33610
aMean day of death of hamsters dying prior to day 28.
bDetermined on day 7 of infection; 5 hamsters per treatment group.
cLog10 cell culture 50% infectious dose (CCID50)/g of liver or ml of serum. Percentage of animals presenting with detectable virus levels are indicated in parenthesis.
dAlanine aminotransferase; measured in international units per liter.
*P,0.05;
**P,0.01;
***P,0.001 compared to 0.4% CMC placebo-treated hamsters.
doi:10.1371/journal.pone.0003725.t001
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PLoS ONE | www.plosone.org 3 November 2008 | Volume 3 | Issue 11 | e3725Figure 1. Serum and tissue virus burden during the course of PICV infection in hamsters. All daily sacrifice groups had 4 hamsters/group
except for the day-0 control group, which had 3 animals. Due to death prior to time of sacrifice, tissue and serum samples could only be obtained for
2 and 1 hamsters for the day 9 and 10 groups, respectively. The serum sample was unobtainable from 1 of the day-8 hamsters due to death just prior
to sacrifice. (A) Serum, (B) liver, (C) spleen, (D) kidney, (E) lung, (F) intestinal, and (G) brain virus titers were determined by infectious virus cell culture
assay. Data points represent viral loads for individual hamsters with the group mean represented by the respective horizontal bar.
doi:10.1371/journal.pone.0003725.g001
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minimal fluctuation through day 6 of the infection, before spiking
to peak levels on days 7–9 (,6.5 log10; Figure 1D). Despite the
similar trend, kidney virus load was generally 1–2 log10 less
compared to that of spleen. Lung virus was detectable by day 2 of
infection and viral loads increased daily to ,7l o g 10 by days 7 and 8
(Figure 1E). The intestines appeared to be more refractory to
infection as only 1 of 4 animals had detectable virus on day 3 and at
least one hamster in each daily sacrifice group through the first 7
days had undetectable levels of intestinal virus (Figure 1F). All
sacrificed animals from the day-8, -9 and -10 groups presented with
modest intestinal viral burdens, with a mean peak titer of ,6.5 log10
on day 8. As with other tissues, Smee and colleagues found .8l o g 10
of infectious virus in the brains of PICV-infected weanling animals
and viral replicationwasdetectedasearlyasday2[17].Inthisstudy,
virus was not detected in the brain until day 6, with the peak titer of
,6lo g 10detected onday8oftheinfection(Figure1F).Theobserved
difference between the studies is mostlikely due to the factthat Smee
et al. [17] used an infectious PICV inoculum that was 500 times
(1,000 PFU) the amount used in the present study.
In addition to examining the kinetics of infectious virus during the
course of PICV infection ,s e v e r a lc l i n i c a lm a r k e r sa n dt y p eII F N
induction were also assessed. Baseline amounts of ALT and AST
were found through the first 5 days of infection, with a single hamster
having elevated readings for both enzymes on day 6 (Figure 2A, B).
Although markedlyelevatedinmost animalsonday 7, ALT and AST
generally reached peak levels on days 8 and 9. The single surviving
animal on day 10 of the infection presented with relatively lower ALT
and high AST. Type I IFN was also assessed using a bioassay based
on the inhibition of CPE induced by VSV infection of BHK-21 cells
treated with dilutions of serum samples collected on the various days
of infection. A wide-range of IFN titers was observed throughout
most of the experiment without a clear pattern (Figure 2C). IFN
activity was detected as early as day 2 in one of the infected animals
and the highest titers were collectively seen on day 3.
Delayed treatment of PICV-infected hamsters with T-705
and ribavirin
We havepreviously demonstrated that for early stage treatment of
a highly lethal PICV challenge, the lowest effective doses of T-705
and ribavirin were50and 20 mg/kg/day,respectively[8].Sinceour
objective in the present study was to initiate treatment later during
the course of infection when higher viral burdens are encountered,
theT-705andribavirindoseswereincreasedto100 mg/kg/dayand
40 mg/kg/day, respectively, as a means to compare the antiviral
activity of the drugs based on twice their previous lowest effective
doses. Treatments were initiated on days 4, 5 or 6, based on the
longitudinal analysis of the PICV model described above (Figures 1
and 2), and a small preliminary study (data not shown) wherein
treatment initiated by day 4 completely prevented disease and
inhibited viral replication in a small number of animals, with some
evidence of protection when initiated on day 6.
Hamsters treated orally with 100 mg/kg/day of T-705 starting 4
or 5 days post challenge with PICV survived an infectious inoculum
that killed 95% of animals given 0.4% CMC placebo (Figure 3A). As
seen previously, protection waned if T-705 therapy was initiated on
day 6; however, in this experiment, the reduced efficacy observed
(50% survival) was highly significant compared to the placebo
control (P,0.001). All ribavirin treatments were effective protecting
.80–90% of infected animals from death. Remarkably, many of the
surviving animals treated with ribavirin were generally in poor
condition, smaller and dehydrated compared to surviving animals
that received T-705 or placebo. This observation was borne out in
the analysis of mean group weights that were assessed every 3 days
starting on day 0 (Figure 3B). In all cases, the animals treated with
ribavirinpresentedwiththemostdramaticweightlossthatwasnever
fully recovered in the day-6 treatment group. Although the mean
weights of the animals treated with T-705 were also less than seen in
the sham-infected control animals, all T-705 groups were heavier
(Figure3B)and inbettercondition compared totheribaviringroups.
In respective groups of parallel infected and treated hamsters
sacrificed on day 7 of PICV infection to measure virological and
liver disease parameters, all treatment groups, with the exception
of the day-6 ribavirin group, had significantly reduced serum and
liver viral titers, with T-705 producing the most dramatic
decreases (Figure 4A, B). As treatments were delayed out to day
6, viral burden increased. This pattern was also evident in the
analysis of serum ALT levels with the early (day-4 initiation)
treatment groups generally having the lowest values (Figure 4C).
Figure 2. Systemic ALT, AST and type I IFN levels during the
courseofPICVinfectioninhamsters.Serumsamplesassayedforviral
burden, as described for Figure 1, were also assayed for (A) ALT, (B) AST,
and(C)typeIIFN.Datapointsrepresentlevelsforindividualhamsterswith
the group mean represented by the respective horizontal bar.
doi:10.1371/journal.pone.0003725.g002
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treated with suboptimal doses of T-705 and ribavirin starting on
day 5 of infection was conducted to investigate whether such a
strategy could reduce the effective dosage of ribavirin in order to
limit its toxicity. Unfortunately, we were not able to achieve the
100% survival obtained with daily doses of 100 mg/kg of T-705 or
60 mg/kg of ribavirin using combinations of smaller doses of each
drug (Table 1). Serum viral titer and ALT data were suggestive of
an additive effect, with a weak indication of improved activity in
the context of liver viral load reduction. The results from this
initial study investigating combination therapy did not warrant
further exploration of synergy between the two drugs.
Treatment of late stage infection with equitoxic doses of
T-705 and ribavirin
Although ribavirin treatment initiated 6 days after challenge
with PICV protected 80% of the animals against death, the mean
weight of the survivors was ,25% less than the 5 animals that
survived the equivalent T-705 treatment. Thus, although ribavirin
appeared to be more effective in the context of survival, the
animals were clearly not as well off as the vast majority of the
survivors from the T-705 treated groups, suggesting underlying
toxicity. Consequently, we next used approximate equitoxic doses
of T-705 and ribavirin to treat PICV infection. Treatments were
initiated on days 5, 6 or 7 with an initial loading dose that is
approximately 10-fold less than the LD50. Because the LD50 of T-
705 in hamsters is .1,500 mg/kg/day, for a 7-day twice a day
regimen [8], we assigned 1,600 mg/kg/day as the LD50, which is
likely an underestimate. The LD50 for ribavirin in hamsters treated
by the same route and schedule is 220 mg/kg/day [8]. Therefore,
T-705 was dosed at 160 mg/kg/day on the first day and 80 mg/
kg/day thereafter, and ribavirin was given at 22 mg/kg/day on
the first day and 11 mg/kg/day afterwards. When treatment was
Figure 3. Effect of delayed T-705 and ribavirin therapy on PICV
infection outcome in hamsters. Drugs were given orally twice per
day for 7 days. Treatments were initiated on day 4, 5 or 6. T-705 was
administered as a daily dose of 100 mg/kg. Ribavirin was dosed at
40 mg/kg/day. Ten animals per group (20 for the placebo) were
observed daily for 4 weeks for (A) survival and every third day for (B)
mean group weight determination of survivors. ***P,0.001 compared
to 0.4% CMC placebo-treated hamsters.
doi:10.1371/journal.pone.0003725.g003
Figure 4. Reduction of viral load and liver disease in PICV-
challenged hamsters following delayed treatment with T-705
and ribavirin. Five hamsters per group were treated as described in
Figure 3, and sacrificed on day 7 of the infection to assess (A) systemic
and (B) hepatic viral burden, and liver disease as determined by (C) ALT
measurement. Data points represent values for individual animals and
mean virus titers and ALT levels for each group are represented by
horizontal lines. *P,0.05; **P,0.01 compared to 0.4% CMC placebo-
treated hamsters.
a P,0.05 compared to hamsters receiving ribavirin
treatment starting on the same day.
doi:10.1371/journal.pone.0003725.g004
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the T-705 regimen were protected (Figure 5A). Compared to the
ribavirin treatment group which had 50% mortality, T-705
treatment significantly improved survival outcome at the equitoxic
doses tested when initiated 5 days after infection. Notably, the
average weights of the ribavirin-treated animals recovering from
PICV challenge were less than those of the survivors from the
other experimental groups (Figure 5B).
When treatment was delayed until day 6 of the infection, both
ribavirin and T-705 protected 50% of the animals, but ribavirin
greatly extended the time-to-death (Figure 5A). Average weights
were comparable between the two drug treatment groups late in the
experimentwhenthe survivinganimalswererecoveringfromdisease
(Figure 5C). Treatments withheld until day 7 were only slightly
beneficial, in that death was delayed in a few of the animals
(Figure 5A). Remarkable weight loss was observed for the ribavirin-
treated animals and the sole survivor was grossly underweight
(Figure 5D) andataxic onday 28. Onlyone otheranimal(in theday-
5 ribavirin treatment-initiation group) presented with a similar
condition at the conclusion of the study. These two animals, as well
as a large cohort of survivors from the other groups, were examined
for brain and serum viral titers on day 28. Detectable amounts of
virus were not present inany of the samples using the infectious virus
assay employed (data not shown), which had a limit of detection of
2.8 log10 CCID50/g of tissue or 1.8 log10 CCID50/ml of serum.
In the evaluation of viral burden in hamsters sacrificed on day 7,
the T-705 treatment initiated on day 5 significantly reduced both
systemic and liver tissue viral loads compared to the placebo group,
with .5 . 5a n d3l o g 10 reductions observed, respectively (Figure 6A,
B). The day-5 ribavirin treatment also significantly reduced viral
burden, but to a lesser degree. All other drug treatment groups had
only minimal, if any, impact on viral burden. Only the day-5 T-705
group significantly prevented liver damage as determined by
measurable ALT activity found in the serum (Figure 6C). Notably,
the day-5 ribavirin group also presented with lower ALT values;
however, this may be a reflection of the extended survival time seen
in the animals that eventually perished.
High-doseT-705treatmentoflatestagePICVvirusinfection
It is possible that a higher initial dose of T-705 may be more
effective in reducing the massive viral burden that is present in
infected hamsters on day 7. A more aggressive dosing regimen may
result in significant protection of challenged animals when initiating
treatment at such an advanced stage. Thus, an experiment was
designed wherein a loading dose of 320 mg/kg would be used for the
first day, followed by 7 days of treatment with 100 mg/kg/day. By
doubling the dose and extending the duration of treatment, we were
able to protect a significant (Fisher’s exact two-tailed test, P=0.0077;
log-rank test, P=0.0577) number of hamsters when initiating
treatment on day 7 (Figure 7). Interestingly, the 40% survival
observed in the day-7 treatment group was similar to the 50% survival
seen when treatment was initiated a dayearlier.Notably,however,the
precipitous survival curve for the day-7 group closely resembled those
of the placebo-treated groups, whereas those animals that started
receiving T-705 a day earlier survived 5–15 days longer (Figure 7).
As in the previous experiments, parallel infected and treated
hamsters were sacrificed on day 7 of PICV infection to examine
the impact of treatment on viral load and liver disease. In addition
to serum and liver viral burden, titers were also assessed for spleen
tissue in this experiment, as it is a major target organ for PICV
infection in hamsters [21]. Although titers were not significantly
reduced by T-705 treatment initiated the day prior to sacrifice,
mean viral loads were generally lower in the animals that received
T-705 (Figure 8A–C). Mean serum ALT concentrations were also
Figure 5. Effect of delayed treatment with equitoxic doses of T-
705 and ribavirin on PICV infection in hamsters. Drugs were
given orally twice per day for 7 days starting on day 5, 6 or 7 for the
drug-treated groups and day 7 for the placebo group. T-705 was dosed
at 160 mg/kg/day on the first day and 80 mg/kg/day thereafter.
Ribavirin was given at 22 mg/kg/day on the first day and 11 mg/kg/day
thereafter. Hamsters were observed 28 days for (A) survival and weights
and standard deviations of survivors are shown for treatments initiated
on day (B) 5, (C) 6 or (D) 7. The 0.4% CMC-treated placebo and sham-
infected, untreated groups are included in B–D for comparison. For the
survival analysis, *P,0.05; ***P,0.001 compared to placebo-treated
hamsters by log-rank test.
a P,0.05 compared to hamsters receiving
ribavirin treatment starting on the same day.
doi:10.1371/journal.pone.0003725.g005
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treated animals having serum ALT .1,000, compared to only
40% for the T-705 group (Figure 8D).
Reduced plasma concentrations of T-705 during late
stage infection
It is conceivable that reduced plasma concentrations of orally
administered T-705 may result as a consequence of altered gastric
absorption, tissue distribution, and/or elimination of the drug in
sick animals. Lower concentrations of T-705 would limit the
amount of available drug to combat the high PICV loads present
upon initiation of treatment on day 6 and 7. This possibility was
investigated by HPLC analysis of plasma taken from PICV-
infected and sham-infected animals given oral T-705 on day 7 of
infection. Plasma T-705 and T-705M1 concentrations from
infected and uninfected animals are compared in Figure 9. T-
705 was quickly absorbed into the circulation of sham-infected
animals achieving plasma concentrations comparable with previ-
ously conducted PK studies in hamsters and mice (Y. Furuta et al.,
unpublished data). In contrast, T-705 concentrations in PICV-
infected animals demonstrated vastly different kinetics, with
dramatically lower concentrations seen at the early time points,
followed by a peak at the 1 h time point, with a sharp decline at
2 h (Figure 9). Notably, the dead-end metabolite, T-705M1, was
more prominently found in the infected animals with much higher
ratios of T-705M1:T-705 being observed compared to the sham-
infected hamsters. It is possible that a defect in the elimination or
distribution of the T-705M1 metabolite may be causing this shift.
Discussion
Here, we describe effective late stage treatment of a severe
arenaviral infection that serves as a model of arenaviral HF with the
novelpyrazinederivative,T-705.Inadditiontothemainobjectiveof
determining whether T-705 therapy could be effective when
delaying the onset of treatment, the efficacy of T-705 was also
compared to that of ribavirin, as it is currently the only antiviral
considered for use for the treatment of arenaviral HFs [7,22].
Notably, the ribavirin-treated animals generally lost considerably
more weight than those receiving T-705 and survivors recovered
more slowly as indicated by the lowest levels of weight recuperation
at the conclusion of the studies. Conceivably, residual toxic effects
due to the treatment may have weakened the animals while
combating the infection, thus attenuating the recovery process.
In the first efficacy experiment, the mean day of death for the T-
705-treated animals in the day-6 initiation group (12.465.4) was 3
days later than in the placebo group (9.260.6), while the animals
treated with ribavirin did not begin to die until the twentieth day
of the infection, well after the treatments had ceased. It is possible
that the viral infection may have rebounded in some of the
ribavirin-treated animals following the end of treatment. Extend-
ing the duration of treatment may have resulted in increased
protection by ribavirin. Nevertheless, there is uncertainty in this
Figure 6. Reduction of viral load and liver disease in PICV-
challenged hamsters following delayed treatment with equi-
toxic doses of T-705 and ribavirin. Five hamsters per group were
treated as described in Figure 5, and sacrificed on day 7 of the infection
to assess (A) systemic and (B) hepatic viral burden, and (C) ALT. The day-
7 treatment initiation group only received the morning dose, with
animals sacrificed 3-4 h after treatment. Data points represent values
for individual animals and mean virus titers and ALT levels for each
group are represented by horizontal lines. *P,0.05; **P,0.01
compared to 0.4% CMC placebo-treated hamsters.
a P,0.05 compared
to hamsters receiving ribavirin treatment starting on the same day.
doi:10.1371/journal.pone.0003725.g006
Figure 7. Survival outcome following high-dose treatment of
advanced PICV infection in hamsters. T-705 or placebo was given
orally twice per day for 8 days starting on day 6 or 7. T-705 was dosed at
320 mg/kg/day on the first day and 100 mg/kg/day thereafter.
Hamsters were observed 28 days for survival. ***P,0.001 compared
to respective placebo-treated hamsters by log-rank test.
doi:10.1371/journal.pone.0003725.g007
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during the 7-day treatment regimen.
It is important to note that because of its lower toxicity, we were
not able to determine an LD50 for T-705, as a 1,500 mg/kg/day
dosing regimen only caused temporary weight loss [8]. Therefore,
the estimated LD50 used to determine the T-705 dose used in the
second study comparing administration of equitoxic amounts of
drug is likely an underestimation of the actual T-705 toxicity. With
that said, T-705 therapy was more effective than ribavirin at
protecting animals from death and limiting viral replication and
liver disease when treatments were initiated on day 5 of PICV
infection. Interestingly, in the equitoxic dosing study, as well as the
initial evaluation, ribavirin was as effective or better in the context
of survival when treatment was delayed until day 6. This trend,
however, was not observed when treatment was begun on day 7,
as only a slight hint of protection was seen with either drug.
Currently, ribavirin is the only drug that has demonstrated
efficacy in humans when administered i.v. within 6 days from the
onset of illness [6]. The idea that T-705 and ribavirin impart their
antiviral activities in different ways suggests that they may act
synergistically in treating arenaviral infections and ultimately
provide the most robust treatment modality. Unfortunately, there
was no evidence of synergy with the combined therapy employing
a limited amount of suboptimal doses of ribavirin and T-705 with
treatments initiated 5 days after PICV challenge. Studies
investigating the potential combination of T-705 and ribavirin in
nonhuman primate models of arenaviral HF may be warranted.
During the temporal analysis of viral burden in hamster tissues,
we found that PICV is initially detectable in the brain by day 6 of
infection in most animals. Lassa virus does not generally cause
neurologic disease, although the virus has been isolated from CNS
fluid [23]. In contrast, infections with Junin virus can produce
encephalitic disease [24,25,26]. An interesting observation result-
ing from the efficacy studies was that several of the smaller
ribavirin-treated survivors appeared to be very uncoordinated with
mild ataxia during the end stages of the experiments, suggesting
neurologicdisease.Tofurtherinvestigatethispossibility,themajority
of the surviving hamsters from the second experiment, where
equitoxic doses of T-705 and ribavirin were compared, were assayed
for the presence of infectious virus in the brain on day 28. No
detectable virus was found in the brains or serum of any of the
animals sampled. The lack of measurable virus in the brain of
hamsters presenting with mild ataxia and tremors observed only in
two of the survivors that hadbeen treated with ribavirin suggests that
signs of neurologic disease may be due to immunopathology,
secondary effects of other system damage, or viral load less than the
limit of measure. Additional investigation into this matter may be
warranted and would require histopathological and immunohisto-
chemical analysis of brain and spinal cord tissue.
Remarkably, significant efficacy was observed with high-dose
(320 mg/kg/day loading, 100 mg/kg/day thereafter) oral T-705
therapy initiated as late as day 7, a stage when peak systemic and
tissue viral titers are evident in most tissue compartments. In the
majority of cases, animals sacrificed on day 7 had maximal viral
Figure 8. Effect of delayed high-dose T-705 therapy on viral burden and liver disease in PICV-challenged hamsters. Five hamsters per
group for the treatment groups initiated on day 6 were treated as described in Figure 7, and sacrificed on day 7 of the infection to assess (A) systemic,
(B) splenic, and (C) hepatic viral loads, and (D) ALT. Data points represent values for individual animals and mean virus titers and ALT levels for each
group are represented by horizontal lines.
doi:10.1371/journal.pone.0003725.g008
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greatest levels of mortality observed in groups wherein treatments
were initiated at such advanced stages of disease. Although we were
able to extend the time to death in animals treated with high-dose
T-705 starting on day 6 of PICV infection, 50% of the hamsters
eventually succumbed. Close examination of viral burden and ALT
concentrations in the animals that began treatment on day 6
suggests that there may be certain thresholds for these parameters
that once reached are strong prognosticators of mortality, despite
therapeutic intervention. Indeed, in human Lassa fever cases,
viremia and serum AST levels are strong predictive factors of
disease outcome [6]. Alternatively, the dramatically lower T-705
plasma concentrations observed in hamsters treated on the seventh
day of infection may also result in animals treated on day 6. This
reduced amount of systemic T-705 may be sub-optimal to combat
the advanced stage arenaviral infection.
Considering that panorganotropic arenaviral infections may
diminish kidney function, in-depth analysis of the effects of PICV
infection on T-705 PK, pharmacodynamics, biodistribution, and
metabolism, all of which may limit the therapeutic timeframe, are
warranted. Moreover, comprehensive longitudinal studies to
clearly define the relationship between T-705 efficacy and p.o.
absorption are needed. Because reduced plasma concentrations of
T-705 in infected animals following oral T-705 administration was
so prominent on day 7, it may be possible to improve upon the
current levels of protection observed by administering T-705 i.v.
During severe disease, patients are often too sick to swallow oral
medications, and may be too volume-depleted to absorb and
distribute a drug that arrives in the stomach. Consequently, i.v.
administration would likely be the standard of care. In hamsters,
however, it is not currently possible to treat i.v., as there is
currently no feasible way to effectively administer drug treatments
multiple times per day for an extended period of time. We are
currently exploring retro orbital i.v. injection as a potential means
of evaluating T-705 efficacy at times when gastric absorption is
depleted and increased vascular permeability would likely hinder
drug absorption following i.p., intramuscular, or subcutaneous
delivery. In addition, studies are being designed to evaluate T-705
in cell culture and animal models based on infection with
authentic highly pathogenic arenaviruses such as Lassa and Junin
viruses.
The mechanism of action of T-705 against arenaviruses is not
known. Against influenza A virus (IAV), time-of-addition studies
with T-705 showed that the drug targets an early to middle stage
of the viral replication cycle that involves viral polymerase activity.
In competitive inhibition studies, the anti-IAV activity of T-705
was reduced by the addition of purines and purine nucleosides
indicating that T-705 functions as a purine analog. Further, T-
705RTP inhibited IAV RNA-dependent RNA-polymerase
(RdRp) in a dose-dependent and GTP-competitive manner.
Importantly, T-705 was not found to inhibit cellular DNA and
RNA synthesis, which are processes inhibited by ribavirin and
other inhibitors of cellular inosine monophosphate dehydrogenase
(IMPDH), a key enzyme in the purine salvage pathway [27].
Studies are currently underway to determine whether selective
inhibition of New World arenaviral RdRp will be the principal
mechanism of T-705 action. The reduced toxicity of T-705 and its
broad-spectrum activity against a number of RNA viruses may
result from its ability to target RdRp domains, since they are not
present in the host and are conserved among RNA viruses.
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